Candence (CADX) has announced early approval for OFIRMEV, its intravenous acetaminophen therapy for pain. Press release can be found here.
So the big question now is ‘What are all those shorts gonna do?’. With a considerable portion of float currently short, it’ll be interesting when CADX opens up for trading this evening.
Congrats to the Cadence longs (or those who were accidentally long through the early approval)!
Disclosure: No positions.
[[T_F]]Data Leak Prevention – Data Security Solutions – Information Theft Protection, Detection and Prevention Software Productstracefusion_signature=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[[T_F]]
BioTech InvestmentParadigm.com
